Chronic Hepatitis C (CHC) is prevalent amongst 130 to 150 million people across the globe
which is mainly due to the exposure of blood or body fluids. Hepatitis C Virus (HCV) is responsible for 8,000-12,000 death per year around the world.The most affected regions are Africa and Central & East Asia. Depending on the country, hepatitis C infection can be concentrated in certain populations (for example, among people who inject drugs) and/or in general populations (Source: WHO: World Health Statistics 2016).
Lack of active screening, care and treatment therapies are some of the major causes responsible for the prevalence of Hepatitis C. In addition, chronic hepatitis C imposes a substantial economic burden on patients, families and the society. Individuals with HCV infection are heavy users of health care institutions and systems. HCV prevalence readily increases the health care costs by more out-patient care, hospitalization and emergency room utilization (Source: The Impact of Hepatitis C Burden: An Evidence-Based Approach).
Hepatitis is a detrimental infection that leads to liver damage; however, early treatment of hepatitis C is effective. There is a surprising dearth of information about hepatitis prevalence, although more is known about its risk factors. Pakistan is the second highest prevalent country, where about 10 million people are affected from Hepatitis C (Source: JPMS- A Silent Storm: Hepatitis C in Pakistan), which makes 5% of the total country population. In global context, Pakistani population affected by Hepatitis C makes about 6.6% of the global Hepatitis C population. As a developing country with per capita income of USD 1,513 per year (Source: Express Tribune May 20, 2015) and with population of 60 million Pakistanis living below the poverty line (in monetary terms, poverty line stands at Rs 3,030 per adult equivalent per month) (Source: DAWN Apr 08, 2016) and with such alarming conditions regarding Hepatitis C prevalence in the country, a lot needs to be done in the field of hepatitis C medicines and clinical research.
Partnering for the solution of Hepatitis C prevalence in Pakistan, OBS has helped many patients with “PegIntron”, and introduced (Sofosbuvir 400 mg Tablets) from Mylan, World’s 2nd Largest Specialty & generic company in March 2016. This has led to efficient practice prevention and exercise caution from Hepatitis C. Sindh Provincial Chief Minister Program for the control of Hepatitis C helps and supports thousands of patients across Sindh for the awareness and treatment of Hep C. In this regard, government usually prefers innovative brands for the treatment of CHC. OBS takes pride in the fact that PegIntron was the first molecule, which was selected for the same disease and is being in use by many patients across Sindh. This initiative has immensely contributed to the reduction of Hepatitis prevalence in Sindh. In addition, one more innovative brand from OBS was selected for the benefit of CHC patients in Sindh to cater thousands of Hepatitis C patients in Pakistan. With such business excellence, Hepatitis can be readily prevented and controlled in Pakistan. OBS believes that this is just the beginning of brand excellence that is to continue in years to come.